Intra-Cellular Therapies Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 2.07
Dividend & YieldN/A$ (N/A)
Beta 1.14
Market capitalization 5.01B
Operating cash flow -304.18M
ESG Scores unknown

Company description

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Sector: Healthcare - Industry: Drug Manufacturers—Specialty & Generic

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 8.32M -6.27M -1.66M 3.19M
Total Cashflows From Investing Activities 134.64M 177.44M -480.3M 280.34M
Net Borrowings
Total Cash From Financing Activities 685.19k 3.24M 664.18M 11.52M
Change To Operating Activities 11.63M 5.68M -7.8M 740.84k
Issuance Of Stock 685.19k 3.24M 664.18M 11.52M
Net Income -155.13M -147.72M -227.01M -284.13M
Change In Cash 17.16M 52.69M -46.19M 32.32M
Effect Of Exchange Rate
Total Cash From Operating Activities -118.17M -127.98M -230.07M -259.54M
Depreciation 368.67k 477.12k 528.12k 533.36k
Change To Account Receivables -10.76M -10.76M -10.76M -9.39M
Other Cashflows From Financing Activities
Change To Netincome 16.65M 19.85M 23.68M 30.4M
Capital Expenditures -391.27k -700.39k -266.72k -325.74k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development
Income Before Tax -155.13M -147.72M -226.99M -284.12M
Net Income -155.13M -147.72M -227.01M -284.13M
Selling General Administrative 30.1M 64.95M 186.36M 272.61M
Gross Profit -132.17M -89.06M -44.86M -13.08M
Ebit -162.27M -154.01M -231.23M -285.69M
Operating Income -162.27M -154.01M -231.23M -285.69M
Interest Expense
Income Tax Expense 1.6k 1.6k 13.51k 5.63k
Total Revenue 60.61k 22.81M 83.8M
Cost Of Revenue 132.17M 89.12M 67.68M 96.88M
Total Other Income ExpenseNet 7.14M 6.29M 4.24M 1.57M
Net Income From Continuing Ops -155.13M -147.72M -227.01M -284.13M
Net Income Applicable To Common Shares -155.13M -147.72M -227.01M -284.13M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 39.49M 56.18M 60.45M 72.03M
Total Stockholder Equity 317.71M 195.01M 656.86M 417.89M
Other Current Liabilities
Total Assets 357.21M 251.19M 717.31M 489.92M
Common Stock 5.49k 5.55k 8.05k 8.19k
Other Current Assets 1.4M 1.4M
Retained Earnings -562.38M -710.1M -937.1M -1.22B
Treasury Stock -667.76k 128.32k 480.58k -363.65k
Cash 54.95M 107.64M 60.05M 92.36M
Total Current Liabilities 36.3M 36.22M 36.85M 53.36M
Other Stockholder Equity -667.76k 128.32k 480.58k -363.65k
Property, Plant, and Equipment 1.16M 20.51M 26.32M 22.56M
Total Current Assets 355.44M 230.32M 690.9M 467.28M
Net Tangible Assets 317.71M 195.01M 656.86M 417.89M
Net Receivables 10.76M 20.16M
Accounts Payable 13.96M 7.43M 5.5M 8.69M


Insider Transactions

Here are the insider transactions of stock shares related to Intra-Cellular Therapies Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
MARCUS JOEL SSale at price 52.11 - 52.49 per share.D2022-11-07Director10k
RIGGS RORY BStock Award(Grant) at price 46.53 per share.D2022-09-30Director365
VAN NOSTRAND ROBERT LStock Award(Grant) at price 46.53 per share.D2022-09-30Director110
HINELINE LAWRENCE JSale at price 45.39 - 45.88 per share.D2022-09-21Chief Financial Officer65.16k
HINELINE LAWRENCE JConversion of Exercise of derivative security at price 15.47 per share.D2022-09-21Chief Financial Officer65.16k
VAN NOSTRAND ROBERT LSale at price 56.80 - 57.15 per share.D2022-08-11Director30k
VAN NOSTRAND ROBERT LConversion of Exercise of derivative security at price 12.45 - 13.05 per share.D2022-08-11Director30k
MARCUS JOEL SSale at price 59.22 per share.D2022-08-11Director10k
RIGGS RORY BStock Award(Grant) at price 57.08 per share.D2022-06-30Director289
VAN NOSTRAND ROBERT LStock Award(Grant) at price 57.08 per share.D2022-06-30Director108
MARCUS JOEL SSale at price 55.00 per share.D2022-05-12Director10k
NEUMANN MARKSale at price 63.55 - 65.14 per share.D2022-04-08Officer86.35k
NEUMANN MARKConversion of Exercise of derivative security at price 12.73 per share.D2022-04-08Officer86.35k
RIGGS RORY BStock Award(Grant) at price 61.19 per share.D2022-03-31Director257
VAN NOSTRAND ROBERT LStock Award(Grant) at price 61.19 per share.D2022-03-31Director126
RIGGS RORY BSale at price 58.72 - 61.35 per share.I2022-03-18Director226.67k
MATES SHARONConversion of Exercise of derivative security at price 2.84 per share.D2022-03-09Chief Executive Officer38.92k
MARCUS JOEL SSale at price 52.25 - 54.52 per share.I2022-03-08Director20k
DURGAM SURESH K. M.D.Sale at price 55.52 - 56.98 per share.D2022-03-04Officer8.04k
HINELINE LAWRENCE JSale at price 50.94 - 52.38 per share.D2022-02-24Chief Financial Officer7.45k
MATES SHARONSale at price 50.92 - 52.35 per share.D2022-02-24Chief Executive Officer22.59k
HALSTEAD MICHAEL I.Sale at price 51.62 - 52.38 per share.D2022-02-24General Counsel7.91k
NEUMANN MARKSale at price 51.33 - 52.94 per share.D2022-02-24Officer7.91k
DURGAM SURESH K. M.D.Sale at price 51.33 - 53.04 per share.D2022-02-24Officer4.05k
HINELINE LAWRENCE JD2022-02-23Chief Financial Officer7.45k
MATES SHAROND2022-02-23Chief Executive Officer22.59k
HALSTEAD MICHAEL I.D2022-02-23General Counsel7.91k
NEUMANN MARKD2022-02-23Officer7.91k
DURGAM SURESH K. M.D.D2022-02-23Officer7.91k
HINELINE LAWRENCE JSale at price 54.99 - 55.72 per share.D2022-02-22Chief Financial Officer10.44k
MATES SHARONSale at price 54.98 - 55.73 per share.D2022-02-22Chief Executive Officer27.85k
HALSTEAD MICHAEL I.Sale at price 54.98 - 55.69 per share.D2022-02-22General Counsel11.14k
NEUMANN MARKSale at price 54.84 - 55.60 per share.D2022-02-22Officer11.14k
DURGAM SURESH K. M.D.Sale at price 54.80 - 55.53 per share.D2022-02-22Officer4.18k
HINELINE LAWRENCE JD2022-02-18Chief Financial Officer10.44k
MATES SHAROND2022-02-18Chief Executive Officer27.85k
HALSTEAD MICHAEL I.D2022-02-18General Counsel11.14k
NEUMANN MARKD2022-02-18Officer11.14k
DURGAM SURESH K. M.D.D2022-02-18Officer8.35k
DURGAM SURESH K. M.D.Sale at price 42.03 per share.D2022-01-18Officer6.22k
HINELINE LAWRENCE JSale at price 40.07 - 41.61 per share.D2022-01-10Chief Financial Officer19.64k
MATES SHARONSale at price 40.10 - 41.72 per share.D2022-01-10Chief Executive Officer41.9k
HALSTEAD MICHAEL I.Sale at price 40.12 - 41.74 per share.D2022-01-10General Counsel19.64k
NEUMANN MARKSale at price 40.09 - 41.74 per share.D2022-01-10Officer20.95k
DURGAM SURESH K. M.D.Sale at price 39.83 - 41.48 per share.D2022-01-10Officer6.87k
HINELINE LAWRENCE JD2022-01-07Chief Financial Officer19.64k
MATES SHAROND2022-01-07Chief Executive Officer41.9k
HALSTEAD MICHAEL I.D2022-01-07General Counsel19.64k
NEUMANN MARKD2022-01-07Officer20.95k
DURGAM SURESH K. M.D.D2022-01-07Officer13.09k
RIGGS RORY BStock Award(Grant) at price 52.34 per share.D2021-12-31Director300

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Intra-Cellular Therapies Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Intra-Cellular Therapies Inc

Here is the result of two systematic investment strategies applied to Intra-Cellular Therapies Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Intra-Cellular Therapies Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Intra-Cellular Therapies Inc:

Intra-Cellular Therapies Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 169.78% on the backtest period.

Performance at glance

Performance

169.78 %

Latent gain

2951.75 $

Invested capital

1738.6 $

Annualized return

41.41 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Intra-Cellular Therapies Inc

This is the result of two momentum investment strategies applied to Intra-Cellular Therapies Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Intra-Cellular Therapies Inc

The following chart shows all the entries opened by the momentum investment system on Intra-Cellular Therapies Inc:

Intra-Cellular Therapies Inc momentum entries
  • The first momentum investment strategy would give 198.75% of return on Intra-Cellular Therapies Inc. That represents 9390.72$ of latent gain with 4725.0$ of employed capital.
  • The second momentum investment strategy would give 122.46% of return on Intra-Cellular Therapies Inc. That represents 4868.81$ of latent gain with 3975.85$ of employed capital.
Performance at glance (1Q Momentum)

Performance

198.75 %

Latent gain

9390.72 $

Invested capital

4725.0 $

Annualized return

98.43 %
Performance at glance (2Q Momentum)

Performance

122.46 %

Latent gain

4868.81 $

Invested capital

3975.85 $

Annualized return

33.83 %

Momentum equity curve on Intra-Cellular Therapies Inc

The following chart shows the equity curve of the two momentum strategies applied to Intra-Cellular Therapies Inc:

Intra-Cellular Therapies Inc momentum equity

Note: the dividends potentially given by Intra-Cellular Therapies Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Intra-Cellular Therapies Inc

The following chart shows the employed capital evolution of the two momentum strategies on Intra-Cellular Therapies Inc since the beginning:

Intra-Cellular Therapies Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Intra-Cellular Therapies Inc

Buy the dip entry openings on Intra-Cellular Therapies Inc

Intra-Cellular Therapies Inc

The performance achieved by the robo-advisor on Intra-Cellular Therapies Inc is 206.7%. That represents 1023.58$ of latent gain with 495.2$ of employed capital. The following chart shows Intra-Cellular Therapies Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Intra-Cellular Therapies Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

206.7 %

Latent gain

1023.58 $

Invested capital

495.2 $

Annualized return

98.43 %

Equity curve of the strategy applied to Intra-Cellular Therapies Inc

The following chart shows the result of the investment strategy applied to Intra-Cellular Therapies Inc:

Intra-Cellular Therapies Inc

Note: the dividends potentially given by Intra-Cellular Therapies Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Intra-Cellular Therapies Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Intra-Cellular Therapies Inc:

Intra-Cellular Therapies Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Intra-Cellular Therapies Inc

In this section, I will compare the three previous investment strategies applied to Intra-Cellular Therapies Inc.

Equity curve comparison on Intra-Cellular Therapies Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Intra-Cellular Therapies Inc investment strategy comparison

Employed capital comparison on Intra-Cellular Therapies Inc

Intra-Cellular Therapies Inc investment comparison

Performance comparison on Intra-Cellular Therapies Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 169.78% 2951.75$ 1738.6$ 41.41%
Momentum 1 quarter 198.75% 9390.72$ 4725.0$ 51.49%
Momentum 2 quarters 122.46% 4868.81$ 3975.85$ 33.83%
Non-directional 206.7% 1023.58$ 495.2$ 98.43%
Annualized return comparison

Automatic investment

41.41 %

Momentum 1Q

33.83 %

Momentum 2Q

33.83 %

Non-directional

98.43 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Intra-Cellular Therapies Inc:

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

  • Palomar Holdings Inc
  • GREENTOWN CHINA

  • Note: The algorithm computes the probability of correlation between Intra-Cellular Therapies Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Intra-Cellular Therapies Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Intra-Cellular Therapies Inc
    Country United States
    City New York
    Address 430 East 29th Street
    Phone 646 440 9333
    Website www.intracellulartherapies.com
    FullTime employees 512
    Industry Drug Manufacturers—Specialty & Generic
    Sector Healthcare
    Exchange XNAS
    Ticker ITCI
    Market www.nasdaq.com

    Intra-Cellular Therapies Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown